Recruiting

Targeted Drug Therapy After Surgery for Lung Cancer on Both Sides

Plain-English translation of NCT06924398 on ClinicalTrials.gov ↗ · Source last updated June 2025 · Translation generated August 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing EGFR-TKI therapy — a targeted medication that works against specific mutations in lung cancer cells — as a way to treat lung cancer that appears on both sides of the lungs. Instead of having a second surgery to remove tumors on the opposite lung, you would take this medication for three months after your first surgery to try to shrink or control any remaining tumors. The goal is to avoid the risks and recovery time of a second operation.

When lung cancer appears on both lungs, doctors face a difficult choice: perform two surgeries (which carries serious risks) or leave one side untreated (which risks the cancer growing back). This trial exists to see whether taking this medication after the first surgery can safely control the remaining tumors without needing a second operation.

Do you qualify?

You likely qualify if…

you have been diagnosed with a specific type of lung cancer (adenocarcinoma) that has a mutation called EGFR (exon 19 deletion or L858R) and affects both lungs
you have already had surgery to remove cancer from one lung, and the surgery confirmed the EGFR mutation
you have at least one suspected tumor remaining on the other lung that is between 8mm and 3cm in size
your remaining tumors have not shrunk after standard anti-inflammatory treatment
you are in good overall health with a performance status score of 0 or 1 (able to carry out normal activities)

You likely don't qualify if…

you have cancer that has spread to lymph nodes or other parts of your body
you have severe problems with your heart, lungs, liver, or kidneys that would make surgery unsafe
you have had another cancer diagnosis in the past five years
you have a history of interstitial lung disease or previous severe lung injury from medications
you are pregnant, breastfeeding, or unwilling to use birth control during the trial

What participation looks like

After your lung surgery and once you've recovered from any surgical complications, you'll visit the clinic 4–10 weeks later to start the three-month medication treatment. You'll take the EGFR-TKI medication (pills) daily for three months, then return for a CT scan to see if the remaining tumors have shrunk. If the medication causes side effects you can't tolerate, treatment can be stopped. If tumors persist after three months, your doctor team will discuss whether surgery on the other lung is needed.

AI-generated summary from trial data · Aug 8, 2026 · Not medical advice

Trial locations(1 site)

China

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong

Key details

Phase

Testing effectiveness

Sponsor

Sun Yat-sen University

Enrollment target

~32 participants

Started

April 2025

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 75 Years

Last updated on clinicaltrials.gov in June 2025.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

Hong Yang, PhD

Sun Yat-Sen University Cancer Center

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.